Compare NKX & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | ZVRA |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 562.2M |
| IPO Year | N/A | 2015 |
| Metric | NKX | ZVRA |
|---|---|---|
| Price | $11.70 | $12.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 146.4K | ★ 805.7K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $16.27 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $11.68 | $7.16 |
| 52 Week High | $13.20 | $15.04 |
| Indicator | NKX | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 25.22 | 53.00 |
| Support Level | N/A | $11.39 |
| Resistance Level | $12.49 | $12.19 |
| Average True Range (ATR) | 0.09 | 0.43 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 12.28 | 46.95 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.